Health and Healthcare
Amgen Becomes A Biotech Safety Stock (AMGN)
Published:
Last Updated:
Amgen Inc. (NASDAQ: AMGN) has just posted earnings. The biotech giant for anemia treatments posted $1.09 GAAP EPS and adjusted earnings of $1.23 non-GAAP EPS and $3.875 billion in revenues. First Call had estimates pegged at $1.08 EPS on revenues of $3.7 billion.
The company has also now raised full-year guidance to $4.45 to $4.55EPS from the prior range of $4.25 to $4.45 EPS. First call hasestimates at $4.38 EPS.
Aranesp sales were up at $845 million and it saw $634 million in Epogen sales, both of which were above estimates.
Shares closed down over 4.7% at $49.92 for an unofficial closing price,but shares are flying high up around the $53.00 mark in after-hourstrading. The 52-week trading range is $39.16 to $66.51.
Jon C. Ogg
October 22, 2008
Sponsored: Want to Retire Early? Start Here
Want retirement to come a few years earlier than you’d planned? Orare you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
